Objectives. Examine if aortic valve opening (AVO) and other echocardiographic parameters influence outcomes in patients on left ventricular assist device (LVAD) support.
Introduction
Despite improvements in technology with newer generation devices and refinement of anticoagulation protocols, pump thrombosis (PT) is a relatively frequent complication of left ventricular assist devices (LVAD). It is a serious and potentially life threatening event, with mortality rates reported as high as 20% at 30 days with the HeartMate II device (1) . In the ADVANCE trial of the HeartWare (HVAD) device (2) an incidence of 0.08 cases/patient/year was reported, though no increase in mortality.
These discrepancies in mortality rates may in part be due to difficulties in diagnosing or defining PT, so there are concerns about some reports underestimating PT (3) (4). Ischemic stroke (IS) or transient ischemic attack (TIA) due to cardioembolism are also important thrombotic complications of LVAD support, due to thrombus formation within the left ventricle or the LVAD (5) . Incidence was reported recently as 1.61 stroke events/100 patients within the first year after implantation (6) . A number of reasons have been reported as potential factors increasing risk of PT and IS or TIA:
including lower aspirin dose, low INR or high blood pressure (7) .
With limitations in numbers of heart transplantation (8) , patients are inevitably supported for longer durations with LVADs. This leads to increased exposure to risks of these devices, such as thrombotic events. In that respect, the role of aortic valve opening (AVO) and risk of adverse events is not known. Potentially some residual AVO may allow washout of blood from the left ventricle that is not adequately drained by the LVAD, preventing in-situ left ventricular thrombus formation. However, in some cases when the left ventricular function is very poor it may not be possible to preserve any AVO. In this report we focus on the echocardiographic parameters that could influence these thrombotic events.
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Methods
This is a retrospective analysis of patients over 16 years of age that received a HeartWare LVAD (HVAD®, HeartWare Inc, Framingham, MA, United States) as bridge to transplant or bridge to candidacy in the Freeman Hospital, between July 2009 and August 2015, following the standard technique previously described (9) . Anticoagulation and antiplatelet regimes have previously been described (4), and in brief have been since 2011 a target INR of 2.7 and aspirin 300 mg daily. Before that the standard dose of aspirin was 75 mg daily. Patient characteristics and comorbidities as well as incidence of events were described using the Freeman Cardiothoracic Transplant database and electronic health records. This study adhered to the terms of the United Kingdom Data and Protection Act and Freedom of Information Act, and was approved to obtain confidential information by the local Caldicott Guardian.
Thrombotic Events:
We defined an event as the definitive diagnosis of first episode of PT, IS or TIA.
We included only first events in the analysis as second and subsequent events could be related to the source of the first event, such as a partially resolved PT. We created a first "combined thrombotic event" (CTE) that was the sum of the first PT, IS or TIA. Thus, if a patient had a PT initially and then at a later date an IS, only the PT was accounted for in the CTE, and if a patient had a IS initially and then at a later date an PT, only the IS was accounted for in the CTE. From these definitions we were able to analyse time to first thrombotic event. PT was defined as the presence of one or more of the following parameters: persistent increase of pump wattage at rest, significant increase of LDH, need for thrombolysis, or pump exchange that revealed evidence of thrombus within the inflow cannula or outflow graft. We also included patients with a low wattage, low flow state (without any other explanation such as dehydration, bleeding, right ventricular failure or high afterload), that resolved after thrombolysis or underwent pump exchange that revealed evidence of thrombus within the inflow cannula or outflow graft. IS and TIA were diagnosed clinically with appropriate imaging. We excluded intracranial bleeding that was suspicious of a primary cardioembolic event with secondary haemorrhagic transformation, as this is difficult to diagnose with certainty. which if the patient is still alive would be the most recently available or if deceased, the last prior to death. In patients with one of the defined thrombotic events, the last pre-event echocardiogram was reviewed. If this was performed more than 3 months before the event, it was compared with the one performed when the thrombotic event was resolved to establish if this was a representative current assessment of the left ventricle and aortic valve. Echocardiograms performed during the acute phase of a PT were not included as LVEDD and aortic valve opening (AVO) can be affected by the presence of a thrombus. LVEDD, visual estimate of left ventricular ejection fraction (LVEF) and aortic valve opening (AVO) were the variables analysed in the pre-event echocardiogram. LVEF was quantified by visual estimate due to difficulties in using standard measurement methods in this population (10).
LVEDD percentage change or left ventricular dimension decrement index was calculated (LVDDI;
preoperative end-diastolic dimension -subsequent echocardiogram end-diastolic dimension divided by preoperative dimension x100) adapted from a recent description (11).
Aortic Valve Opening:
We created 2 categories for the AVO variable, "Yes" or "No". This required careful categorization. AVO was defined as "Yes" when it opened completely or partially in every cardiac cycle or just sometimes but on a regular basis and "frequently". "Frequently" was a subjective measurement, but for example included those in which the aortic valve opened every third or fourth cardiac cycle. There were a small number of cases in which aortic valve opened less frequently, but nevertheless not so infrequent to be considered closed. In this situation, subsequent echocardiograms in the following weeks or few months were reviewed to check if the trend was to open on a regular basis or the opposite, to define "Yes" or "No" AVO status. AVO was considered closed when it was completely and always closed or when opening was only very occasional or the leaflets moved only slightly without effective transvalvular flow. J Heart Lung Transplant. 2017 Jan;36(1):42-49
Pump speed: Pump speed (rpm; revolutions per minute) was set at the time of implantation to achieve an optimal position of the intraventricular septum, with if possible, some residual AVO. Pump speed was not routinely changed post implant.
Right Heart Catheter. We included haemodynamic data of the first right heart catheterization performed after discharge from the HVAD implantation.
Cohorts of analysis.
We analysed the outcomes of the whole cohort but also created a sub-cohort with at least 30 days of follow-up before a first event. This '30 days out' cohort excluded those patients that died within 30 days of implant, had less than 30 days follow up at the time of analysis (recent implants), and had a thrombotic event before 30 days (as this was felt to represent a different mechanism to later thrombotic events). For these reasons, we concentrated on the "30 days out" cohort in the analysis of thrombotic events.
Data and statistical analysis: Data are presented as mean ± standard deviation (SD) and duration of days as median and mean. Outcome measures used were all-cause mortality and survival on the device using Kaplan-Meier survival curves, comparing above and below mean values for each variable, and the log-rank test for significance. Single unpaired comparisons were made with Student T-test or the Mann-Whitney U-test when data was not normally distributed. We used the Cox proportional hazard model for multivariate analysis. P<0.05 was considered significant. The statistical software used for analyses was SPSS Statistics Version 20. 
Discussion
In this single centre study of 126 HVAD patients with a median of over 500 days follow up, we show that a closed aortic valve was strongly related to adverse outcomes, including CTE-free survival and PT-free survival, as well as increased mortality. Furthermore, less reverse remodelling on support with reduced LVDDI was also related to PT and CTE, and greater LVEDD on support was also associated with increased rates of PT.
Reverse remodelling: Joyce and colleagues have recently described in 64 subjects with the Heartmate II device, that less reverse remodelling of the left ventricle on support was associated with greater risk of pump thrombosis (11) . Comparisons between the current study and Joyce et al are difficult. Nevertheless, with respect to reverse remodelling, we also show that greater reductions in left ventricular size are associated with less adverse events. In that study, the Heartmate II device was used, which has several fundamental differences to the HVAD. Our median time to PT was 13 compared to 8 months, and the protocol for setting pump speeds different. Their incidence of pump thrombosis was 0.06 per patient year compared to our higher rate of 0.15. They performed a predischarge ramp test, whereas our pump speeds were set at the time of LVAD implant. Also, in that series more than 70% had a closed aortic valve compared with less than 40% in the present study.
There are several potential explanations for the higher PT rates in the current study. Compared to other series there is a longer duration of support (11) (12), which can at least partially explain higher thrombotic event rates (as these are related to the duration of support (4)). This is also supported by the fact that our median time to PT is longer than other series (11) . A unique aspect of our study population are the relatively low rates of transplantation in a group of patients in whom the indications were bridge to transplant or bridge to decision (8) . In the ADVANCE trial the rates of transplantation at 6 months were almost 30% (16) , so in that situation, those with potentially life threatening complications on support can receive the bail-out option of a transplant. Our rates of transplantation are much lower (4), with only 4% receiving a transplant at 6 months post implant, so those that developed serious adverse events such as PT, IS or CTE remained at risk for further subsequent events and death. It is also quite possible that some series are underestimating the true PT (13) (14), so this could be a source of thrombus to subsequently migrate through the device causing a PT. We cannot definitively state that all patients with a HVAD should have pump speeds set so that there is AVO. A closed aortic valve is not only a reflection of pump speed, but also right heart function, afterload and intrinsic left ventricular contractility, so those patients who have less AVO in this series maybe more intrinsically at higher risk for adverse outcomes. This contention is supported by the lower ejection fractions and cardiac output in those without AVO, and that pump speeds were not significantly different between the 2 groups. Whether this means that higher pump speeds with a theoretical objective of more left ventricular unloading would improve outcomes, or alternatively just shows that patients with better preserved intrinsic right and left ventricular function have more AVO and therefore less thrombotic adverse events is not known. The most logical way to address this issue would be a randomized controlled trial comparing different pump speed strategies and outcomes Nevertheless, our data show that patients without AVO are at high risk for events and so may benefit from more intense anticoagulation and should even be considered for prioritization for transplantation One aspect of our study population is the relatively high levels of AVO as detailed above (8), and also lower pump speeds than previously reported (9) . We have previously reported the hemodynamic effects of the HVAD in a smaller cohort of patients (15) . At 200 days of support we reported that the left ventricular end-diastolic dimension reduces from 7.2±1.0 to 6.9±1.2 cm (at an average of 2522±174 rpm). In contrast, Gupta et al (12) have shown with their cohort of HVAD patients that at 100 days left ventricular end-diastolic dimension reduces from 7.1±1.3 to 6.1±1.4 cm, though at a higher mean pump speed of 2693±139 rpm, specifically set so that the aortic valve was closed. Thus, our relatively low pump speed settings, and therefore higher rates of AVO, may directly affect our ability to detect these differences in outcomes. Regarding other echocardiographic parameters, we have recently shown that significant aortic regurgitation is very rare and so have not to included this in this analysis (16) . 
